Uracil

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

32 Data

Cimetidine	The serum concentration of Uracil can be increased when it is combined with Cimetidine.
Gemcitabine	The serum concentration of Uracil can be increased when it is combined with Gemcitabine.
Sorafenib	The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Uracil.
Phenytoin	The serum concentration of Phenytoin can be increased when it is combined with Uracil.
Fosphenytoin	The serum concentration of Fosphenytoin can be increased when it is combined with Uracil.
Gimeracil	The serum concentration of Uracil can be increased when it is combined with Gimeracil.
Metronidazole	The serum concentration of Uracil can be increased when it is combined with Metronidazole.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Uracil.
Dicoumarol	The risk or severity of bleeding can be increased when Uracil is combined with Dicoumarol.
Phenindione	The risk or severity of bleeding can be increased when Uracil is combined with Phenindione.
Warfarin	The risk or severity of bleeding can be increased when Uracil is combined with Warfarin.
Phenprocoumon	The risk or severity of bleeding can be increased when Uracil is combined with Phenprocoumon.
Acenocoumarol	The risk or severity of bleeding can be increased when Uracil is combined with Acenocoumarol.
4-hydroxycoumarin	The risk or severity of bleeding can be increased when Uracil is combined with 4-hydroxycoumarin.
Coumarin	The risk or severity of bleeding can be increased when Uracil is combined with Coumarin.
(R)-warfarin	The risk or severity of bleeding can be increased when Uracil is combined with (R)-warfarin.
Ethyl biscoumacetate	The risk or severity of bleeding can be increased when Uracil is combined with Ethyl biscoumacetate.
Fluindione	The risk or severity of bleeding can be increased when Uracil is combined with Fluindione.
Clorindione	The risk or severity of bleeding can be increased when Uracil is combined with Clorindione.
Diphenadione	The risk or severity of bleeding can be increased when Uracil is combined with Diphenadione.
Tioclomarol	The risk or severity of bleeding can be increased when Uracil is combined with Tioclomarol.
(S)-Warfarin	The risk or severity of bleeding can be increased when Uracil is combined with (S)-Warfarin.
Sunitinib	The risk or severity of QTc prolongation can be increased when Uracil is combined with Sunitinib.
Tetrahydrofolic acid	The risk or severity of adverse effects can be increased when Tetrahydrofolic acid is combined with Uracil.
Folic acid	The risk or severity of adverse effects can be increased when Folic acid is combined with Uracil.
Leucovorin	The risk or severity of adverse effects can be increased when Leucovorin is combined with Uracil.
(6S)-5,6,7,8-tetrahydrofolic acid	The risk or severity of adverse effects can be increased when (6S)-5,6,7,8-tetrahydrofolic acid is combined with Uracil.
Triglu-5-formyl-tetrahydrofolate	The risk or severity of adverse effects can be increased when Triglu-5-formyl-tetrahydrofolate is combined with Uracil.
(6R)-Folinic acid	The risk or severity of adverse effects can be increased when (6R)-Folinic acid is combined with Uracil.
5-methyltetrahydrofolic acid	The risk or severity of adverse effects can be increased when 5-methyltetrahydrofolic acid is combined with Uracil.
Levomefolic acid	The risk or severity of adverse effects can be increased when Levomefolic acid is combined with Uracil.
Levoleucovorin	The risk or severity of adverse effects can be increased when Levoleucovorin is combined with Uracil.

Target Protein

Dihydropyrimidine dehydrogenase [NADP(+)] DPYD

Uridine-cytidine kinase-like 1 UCKL1

Uracil-DNA glycosylase

Uracil-DNA glycosylase ung

Ribosomal small subunit pseudouridine synthase A rsuA

Uracil-DNA glycosylase udg

Pyrimidine-nucleoside phosphorylase pdp

Referensi & Sumber

Synthesis reference: Kurt Klemm, Wolfgang Schoetensack, Wolfgang Prusse, "Aryl-substituted piperazinyl-alkylamino-uracils, -uracil ethers and -uracil thioethers and method for their production." U.S. Patent US3957786, issued September, 1951.

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi